source
- As AbbVie’s Crohn’s combo beats Skyrizi in mid-stage test, analysts laud autoimmune visionAbbVie’s next-gen dual-targeting therapy elicited higher rates of remission than its IL-23 inhibitor Skyrizi in a Phase 2a trial of Crohn’s disease, leading analysts to wonder if the blockbuster ca…BioSpace · 1d ago↗ source
- Disc’s rebuffed rare disease drug sets up FDA redo after ‘clean’ Phase 3 sweepDisc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and significantly increased the time patients with erythropoietic protoporphyria w…BioSpace · 1d ago↗ source
- Jury awards $6 million to former MIT professor David Sabatini in defamation caseA Suffolk County jury awarded $6 million in damages to former MIT professor David Sabatini after finding the plaintiff's claims were defamatory. The case stemmed from accusations by a younger coll…